Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4280 (favezelimab) + pembrolizumab in hematologic malignancies
2023-503587-17-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and favezelimab in hematopoietic malignancies, sponsored by Merck & Co. Primary endpoints: Percentage of Participants Experiencing a Dose-limiting Toxicity (DLT), Percentage of Participants Experiencing an Adverse Event (AE) and 1 more. Started Oct 2023; status: completed.
02
Drugs
pembrolizumabfavezelimab
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on 2023-503587-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503587-17-00.